Federated Hermes’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$72.6M Sell
1,123,266
-451,355
-29% -$31.8M 0.12% 199
2025
Q4
$106M Buy
1,574,621
+123,917
+9% +$8.34M 0.18% 138
2025
Q3
$106M Buy
1,450,704
+1,082,638
+294% +$71.9M 0.19% 137
2025
Q2
$19.1M Buy
368,066
+8,529
+2% +$485K 0.04% 438
2025
Q1
$22.9M Sell
359,537
-29,856
-8% -$1.73M 0.05% 374
2024
Q4
$18.6M Sell
389,393
-322,415
-45% -$16.5M 0.04% 425
2024
Q3
$40.7M Buy
711,808
+15,677
+2% +$899K 0.09% 271
2024
Q2
$36.4M Buy
696,131
+191,030
+38% +$8.38M 0.09% 275
2024
Q1
$20.5M Buy
505,101
+45,732
+10% +$1.71M 0.05% 408
2023
Q4
$17M Buy
459,369
+292,926
+176% +$11M 0.04% 425
2023
Q3
$6.36M Buy
166,443
+113,760
+216% +$4.66M 0.02% 638
2023
Q2
$1.9M Buy
52,683
+9,416
+22% +$321K ﹤0.01% 969
2023
Q1
$1.65M Sell
43,267
-21,909
-34% -$1.03M ﹤0.01% 1017
2022
Q4
$3.71M Sell
65,176
-8,665
-12% -$444K 0.01% 742
2022
Q3
$2.92M Sell
73,841
-9,706
-12% -$429K 0.01% 802
2022
Q2
$3.68M Sell
83,547
-2,614
-3% -$113K 0.01% 766
2022
Q1
$3.44M Sell
86,161
-121,862
-59% -$4.34M 0.01% 872
2021
Q4
$8.36M Sell
208,023
-113,693
-35% -$4.24M 0.02% 698
2021
Q3
$13.1M Buy
321,716
+88,438
+38% +$3.7M 0.02% 576
2021
Q2
$10.6M Sell
233,278
-152,659
-40% -$6.76M 0.02% 635
2021
Q1
$16.1M Buy
385,937
+140,064
+57% +$6.39M 0.03% 549
2020
Q4
$10.5M Sell
245,873
-180,047
-42% -$6.47M 0.02% 633
2020
Q3
$11.2M Sell
425,920
-3,346
-0.8% -$93.2K 0.03% 544
2020
Q2
$11.5M Buy
429,266
+369,599
+619% +$8.34M 0.03% 506
2020
Q1
$1.07M Sell
59,667
-255,540
-81% -$4.85M ﹤0.01% 1115
2019
Q4
$5.59M Sell
315,207
-217,310
-41% -$3.76M 0.01% 740
2019
Q3
$8.26M Sell
532,517
-289,266
-35% -$4.76M 0.02% 626
2019
Q2
$14.1M Sell
821,783
-10,460
-1% -$169K 0.03% 463
2019
Q1
$13.4M Buy
832,243
+209,033
+34% +$3.39M 0.03% 461
2018
Q4
$9.12M Buy
623,210
+454,383
+269% +$7.25M 0.02% 528
2018
Q3
$3.07M Buy
168,827
+63,015
+60% +$1.1M 0.01% 948
2018
Q2
$1.78M Sell
105,812
-72,318
-41% -$1.37M 0.01% 1064
2018
Q1
$3.49M Buy
178,130
+87,709
+97% +$1.7M 0.01% 752
2017
Q4
$1.83M Buy
90,421
+35,558
+65% +$654K 0.01% 971
2017
Q3
$953K Sell
54,863
-10,650
-16% -$144K ﹤0.01% 1215
2017
Q2
$840K Buy
65,513
+17,685
+37% +$236K ﹤0.01% 1268
2017
Q1
$620K Buy
47,828
+47,676
+31,366% +$603K ﹤0.01% 1286
2016
Q4
$2K Sell
152
-1,852
-92% -$20.3K ﹤0.01% 2015
2016
Q3
$24K Sell
2,004
-290
-13% -$2.96K ﹤0.01% 1734
2016
Q2
$20K Hold
2,294
﹤0.01% 1749
2016
Q1
$22K Sell
2,294
-2,037
-47% -$19.2K ﹤0.01% 1726
2015
Q4
$75K Buy
4,331
+4,200
+3,206% +$66.9K ﹤0.01% 1606
2015
Q3
$2K Sell
131
-587
-82% -$11.8K ﹤0.01% 1859
2015
Q2
$16K Buy
+718
New +$12.6K ﹤0.01% 1695

Other funds holding HALO

Federated Hermes's HALO Position: Q1 2026 in Review

Federated Hermes reduced its Halozyme (HALO) stake by 29% in Q1 2026, selling an estimated $31.8M and leaving 1,123,266 shares worth $72.6M. The position accounts for 0.12% of the portfolio, ranked #199.

Federated Hermes first reported a position in HALO in Q2 2015 and has held it in 44 quarters since. The position peaked at $106M in Q3 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Federated Hermes held 1,123,266 shares of Halozyme worth $72.6M as of Q1 2026.
  • Federated Hermes sold 451,355 Halozyme shares in Q1 2026, an estimated $31.8M.
  • Halozyme made up 0.12% of Federated Hermes's portfolio in Q1 2026, its #199 holding.
  • Federated Hermes first reported a position in Halozyme in Q2 2015 and has held it in 44 quarters since.
  • Federated Hermes's Halozyme position peaked at $106M in Q3 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.